High-resolution screening for receptors that many medicines target
Official title: A Novel high resolution MS platform for high-throughput screening of G protein-coupled receptors
Funded at Battelle Pacific Northwest Laboratories · NIH-11324211 · Data updated 2026-11-12
This project is creating a faster, more accurate mass spectrometry tool to detect chemical tags on receptors involved in inflammatory diseases, helping researchers develop better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Pacific Northwest Laboratories NIH-funded |
| Lab location | 1 site (Richland, United States) |
| Project start | June 15, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $464,807 |
| NIH project number | 5R01GM149650-04 |
| Project ID | NIH-11324211 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with inflammatory conditions linked to CXCR3 who are willing to donate blood or tissue samples for laboratory analysis would be most relevant to this work.
✕Less likely to help
Patients without conditions involving CXCR3 or those unable/unwilling to provide samples are unlikely to receive direct benefit from this research.
What this research studies
Researchers are combining ultrahigh-resolution ion mobility separation with very accurate mass spectrometry (a SLIM-Orbitrap platform) to pinpoint where receptors called GPCRs gain phosphate tags. They will focus on CXCR3, a receptor linked to inflammatory conditions, and work to separate and identify complex, multi-phosphorylated peptide forms that current methods often miss. The team will use laboratory samples and advanced instruments to improve sensitivity and speed for site-specific phosphorylation mapping. This work aims to make it easier for scientists to see how drugs and ligands change receptor signaling.
Why it matters
Potential benefit: If successful, this could help researchers and clinicians better understand drug effects on receptor signaling and support development of more precise anti-inflammatory therapies.
How similar studies have gone: Mass spectrometry has been used to map protein phosphorylation before, but applying SLIM ion mobility with Orbitrap MS for high-confidence, high-throughput characterization of complex multi-phosphorylated GPCR sites is a novel and less-tested approach.
Where this research is happening
-
Battelle Pacific Northwest Laboratories
Richland, United States Active
Researchers
- Principal investigator: Jacobs, Jon — Battelle Pacific Northwest Laboratories
- Study coordinator: Jacobs, Jon
Related research
Other NIH-funded projects on the same topics.
-
Proteomics Center for MoTrPAC to map exercise effects in human tissues
A research center is studying how physical activity changes proteins and their modifications in muscles and fat to understand exercise benefits for chronic diseases.
-
Islet cell pathways and regulators in early type 1 diabetes
Researchers will study how insulin-producing beta cells deteriorate before type 1 diabetes becomes clinically apparent, using cutting-edge tissue analysis to find molecular clues that could lead to new therapies.
-
Protein targets of nitazenes and their metabolites in human cells
Researchers will map which human brain, heart, and lung proteins interact with nitazene opioids, helping explain why these drugs can be so potent and dangerous.
-
High-throughput multiomic profiling of single cells
A new platform will measure proteins, RNAs, and metabolites in thousands of individual human cells to better understand how cells regulate themselves.
-
Single-cell phospho-proteomics to map breast tumor microenvironment
A researcher will develop a new, highly sensitive single-cell proteomics tool to map proteins and phosphorylation in breast cancer tumor environments, helping doctors tailor treatments.
-
High-Throughput Lipid Profiling with Precise Structures for Phenotypic Screening
A project to develop advanced lipid profiling that can precisely identify lipid structures to help understand and screen diseases like Alzheimer's.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.